Trial design
vitiliginous lesions
This study was designed as a single-blind randomized controlled study, with three parallel group in each patient and allocation ratio of 1:1. Three vitiliginous lesions located at the same part of the body in each participant were simply randomized to receive three different treatment interventions, including bimatoprost 0.01% monotherapy, combination therapy consisting of bimatoprost 0.01%, and NB-UVB phototherapy, and normal saline solution placebo. The treatment duration was 6 months with 1- and 2-month post-treatment follow-ups. The protocol for this study was approved by the Siriraj Institutional Review Board (COA no. Si263/2016). Written informed consent was obtained from all subjects before their enrollment in the study. All methods were performed by the relevant guidelines and regulations.